Search Results for "Drug Class Action Settlement"

01:27 EDT 4th August 2015 | BioPortfolio

Matching Channels

Duocarmycin analogs

Antibody-drug conjugates are designed to combine the specificity of antibodies directed against tumor-associated targets with potent cytotoxity. Upon internalization of the ADC, the antibody-bound c...

CMV Antisense Drug

Bcl-2 Antisense Drug

Tuberculosis Vaccines and Therapeutics

The WHO estimates that the largest number of new tuberculosis (TB) cases in 2008 occurred in the South-East Asia Region, which accounted for 34% of incident cases globally. However, the estimated inci...

PolyXen

PolyXen® is an enabling technology for protein drug delivery.  It uses the natural polymer polysialic acid (PSA) to prolong the active life and improve the stability of therapeutic peptides...

Matching News

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing -- HEB

UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA Frater v. Hemispherx Biopharma, Inc., et al. No. 2:12-CV-07152 WY SUMMARY NOTICE OF PENDENCY OF CLASS ACTION AND PROPOSED ...

Pomerantz Law Firm Announces Summary Notice of Pendency and Proposed Settlement of Hemispherx Biopharma, Inc. Class Action and Settlement Hearing – HEB

UNITED STATES DISTRICT COURT FOR THEEASTERN DISTRICT OF PENNSYLVANIA Frater v. Hemispherx Biopharma, Inc., et al. No. 2:12-CV-07152 WY SUMMARY NOTICE OF PENDENCY OF CLASS ACTION AND PROPOSED SE...

Teva settles in pay-for-delay class action case over sleeping tablet

Israel-based Teva Pharmaceutical Industries has agreed a $512 million settlement in a class-action law…

Laci LeBeau Super Dieter's Tea Proposed Class Action Settlement

WILMINGTON, Del., April 29, 2015 /PRNewswire/ -- A proposed settlement has been reached in a class action lawsuit involving Leaf 123, Inc. (formerly known as Natrol, Inc.), the manufacturer of Laci Le...

Report: Target to pay $10 million in data breach class action

Marianne WilsonTarget Corp. has agreed to pay $10 million in a proposed settlement of a class-action suit related to the company’s 2013 data breach, according to court documents filed Wednesday....

Mechanism of action of First-in-class anti-HIV drug, ABX464, published

ABIVAX, a biotechnology company developing first-in-class anti-viral drugs and vaccines, has announced publication of the mechanism of action of ABX464... The post Mechanism of action of First-in-clas...

Federal Court Approves $335 Million RALI MBS Class Action Global Settlement

NEW YORK, Aug. 3, 2015 (GLOBE NEWSWIRE) -- A Federal Court has finalized a $335 million global settlement of a class action lawsuit brought by New Jersey Carpenters Health Fund on behalf of purchaser...

Hemispherx Biopharma Announces Final Approval of Securities Class Action Settlement

PHILADELPHIA, July 23, 2015 (GLOBE NEWSWIRE) -- Hemispherx Biopharma (NYSE MKT:HEB) announced that the United States District Court for the Eastern District of Pennsylvania has issued an order granti...

Matching PubMed Articles

Nuclear receptor PXR: discovery of a pharmaceutical anti-target.

Transcriptional induction of the gene encoding cytochrome P450 3A oxygenase (CYP3A) causes a prominent class of dangerous drug-drug interactions wherein one drug accelerates the metabolism of another....

Safety nonsteroidal antiinflammatory drugs.

The choice of a specific medication belonging to a drug class is under the criteria of efficacy, safety, cost and suitability. NSAIDs currently constitute one of the most consumed drug in the world, s...

Colchicine: Old and New.

Although colchicine has been a focus of research, debate and controversy for thousands of years, it was only approved by the United States Food and Drug Administration in 2009. Over the past decade, a...

Closer to the site of action; everolimus concentrations in peripheral blood mononuclear cells correlate well with whole blood concentrations.

Everolimus (EVE) is an immunosuppressive drug dosed according to therapeutic drug monitoring in renal transplant recipients. The primary site of action is within activated lymphocytes. Everolimus is a...

Characteristics of non-opioid substance misusers among patients enrolling in opioid treatment programs: A latent class analysis.

Using latent class analysis, this study examined the pattern of non-opioid substance misuse among 19,101 enrollees into 85 opioid treatment programs (OTPs). The most frequent non-opioid drugs were can...

Search Whole site using Google

Loading

Advertisement
 
Advertisement
 
Advertisement Advertisement